[Central nervous system HIV-associated polyarteritis nodosa: long-term outcome].
BACKGROUND
HIV-associated vasculitis is an infrequent entity, and only few data about its long-term evolution is available.


METHODS
We report the long-term outcome of a patient with central nervous system HIV-associated periarteritis nodosa and then discuss the therapeutic options for this class of vasculitis.


CONCLUSIONS
This observation highlights the role of HAART in the treatment of HIV-associated vasculitis. Persistent remission can be obtained when viral replication is under control.
Chiche
L
L
Service de médecine interne, hôpital de la Conception, 147, boulevard Baille, 13385 Marseille, France.
Jean
R
R
Cretel
E
E
Figuarella-Branger
D
D
Durand
J-M
JM
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002494:Central Nervous System Infections / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000627:therapeutic use; D010488:Polyarteritis Nodosa / Q000150:complications* / Q000175:diagnosis; D018119:Stavudine / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014779:Virus Replication; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019469:Indinavir; D016047:Zalcitabine; D018119:Stavudine